Discontinued — last reported Q2 '23
Business Segments · D&A
Pharmaceutical — D&A
Cardinal Health Pharmaceutical — D&A remained flat by 0.0% to $56.25M in Q2 2023 compared to the prior quarter. Year-over-year, this metric grew by 16.6%, from $48.25M to $56.25M. Over 2 years (FY 2021 to FY 2023), Pharmaceutical — D&A shows an upward trend with a 22.1% CAGR.
Analysis
StatementSegment
CategoryEfficiency
SignalContext dependent
VolatilityStable
First reportedQ3 2015
Last reportedQ2 2023
Rolls up toD&A
How to read this metric
An increase often correlates with higher capital investment in infrastructure, while a decrease may suggest aging assets or lower investment levels.
Detailed definition
The non-cash expense allocated to the segment for the systematic reduction in the value of tangible and intangible asset...
Peer comparison
Standard metric used across all capital-intensive industries to normalize operating performance.
Metric ID:
cah_segment_pharmaceutical_depreciation_and_amortizationHistorical Data
3 years
| FY'21 | FY'22 | FY'23 | |
|---|---|---|---|
| Value | $151.00M | $193.00M | $225.00M |
| YoY Change | — | +27.8% | +16.6% |
Range$151.00M – $225.00M
CAGR+22.1%
Avg YoY Growth+22.2%
Median YoY Growth+22.2%
Current Streak2+ years growth
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Cardinal Health's pharmaceutical — d&a?
- Cardinal Health (CAH) reported pharmaceutical — d&a of $56.25M in Q2 2023.
- How has Cardinal Health's pharmaceutical — d&a changed year-over-year?
- Cardinal Health's pharmaceutical — d&a increased by 16.6% year-over-year, from $48.25M to $56.25M.
- What is the long-term trend for Cardinal Health's pharmaceutical — d&a?
- Over 2 years (2021 to 2023), Cardinal Health's pharmaceutical — d&a has grown at a 22.1% compound annual growth rate (CAGR), from $151.00M to $225.00M.
- What does pharmaceutical — d&a mean?
- The annual non-cash cost of wearing out equipment and using up intangible assets in the segment.